SEC Form 4 · accession 0001178913-17-002618
Artemis Therapeutics, Inc. · ATMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian M Culley
Officer — Chief Executive Officer
Period of report
Aug 9, 2017
Accepted (ET)
Sep 5, 2017 · 4:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062128
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.30 | Aug 9, 2017 | A | 242,640 | A | — | Aug 9, 2027 | Common Stock | 242,640 | 242,640 | D |
Explanation of responses
- F1The option, representing a right to purchase 242,640 shares of the Issuer's common stock at an exercise price of $1.30 per share, vests ratably over a 48 month period commencing on the first day of the month following the date of issuance.